-
Mashup Score: 10Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model - 1 year(s) ago
Challenges remain to adopt mRNA vaccines in preventing mother-to-child-transmission, a major cause of new infections in infants. Khandhar et al. report immunogenicity of self-replicating RNA vaccines using a pregnant rabbit model. The authors show that vaccination in pregnant rabbits was well tolerated and promoted passive transfer of antibodies to newborns.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 12Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model - 1 year(s) ago
Challenges remain to adopt mRNA vaccines in preventing mother-to-child-transmission, a major cause of new infections in infants. Khandhar et al. report immunogenicity of self-replicating RNA vaccines using a pregnant rabbit model. The authors show that vaccination in pregnant rabbits was well tolerated and promoted passive transfer of antibodies to newborns.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
Newly developed mRNA vaccines against #Zika and #HIV-1 produce strong antibody responses that transfer from pregnant rabbits to their offspring. @KhandharAmit Read more in @MolTherapy https://t.co/g70eTGbTLg
-
-
Mashup Score: 63
We describe here the use of extracellular vesicles (EVs) as RNA and protein delivery vehicles. We outline the advantages and disadvantage to using EVs as delivery vehicles and posit that EVs will emerge as a bona fide next generation gene and cell therapy delivery approach.
Source: Molecular TherapyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MolTherapy: Extracellular vesicles: the next generation in gene therapy delivery https://t.co/H1r2UtnnIm
-
-
Mashup Score: 0Driving adult tissue repair via re-engagement of a pathway required for fetal healing - 1 year(s) ago
Fetal wound healing is efficient and regenerative. Sen and colleagues identify the oxidant sensor NPGPx as a critical fetal healing factor. The NPGPx pathway is inefficient but present in adult wound healing. It is absent in diabetic wound healing. Tissue nanotransfection induced NPGPx, markedly rescuing physiological healing in diabetic wounds.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
"Driving adult tissue repair via re-engagement of a pathway required for fetal healing" Read more in @MolTherapy: https://t.co/ajtXg9oHfK
-
-
Mashup Score: 6Driving adult tissue repair via re-engagement of a pathway required for fetal healing - 1 year(s) ago
Fetal wound healing is efficient and regenerative. Sen and colleagues identify the oxidant sensor NPGPx as a critical fetal healing factor. The NPGPx pathway is inefficient but present in adult wound healing. It is absent in diabetic wound healing. Tissue nanotransfection induced NPGPx, markedly rescuing physiological healing in diabetic wounds.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
"Driving adult tissue repair via re-engagement of a pathway required for fetal healing" Read more in @MolTherapy: https://t.co/ajtXg9oHfK
-
-
Mashup Score: 8Gene therapy for ALS: A review - 1 year(s) ago
In this review, Davidson and colleague provide an in-depth review of the preclinical and clinical gene therapy advances made in treatment of both inherited and sporadic amyotrophic lateral sclerosis (ALS). They discuss antisense oligonucleotides, RNA interference, CRISPR, AAV-mediated trophic support, and antibody-based methods, highlighting ongoing challenges and anticipated future directions.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
Most-read Molecular Therapy paper: Gene Therapy for ALS: A Review @ASGCTherapy @MolTherapy @lab_davidson @PennMedicine https://t.co/xb0Xku0vjL
-
-
Mashup Score: 0Cellular therapy: Great promise, but at what cost? - 1 year(s) ago
The introduction of chimeric antigen receptor T cell (CAR-T) therapy has been transformative in hematological malignancies. In the US, there are now 6 FDA-approved products across 5 malignancies; acute lymphoblastic leukemia, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and multiple myeloma. These are highly potent treatments that are effective in patients…
Source: Molecular TherapyCategories: Hem/Oncs, Latest HeadlinesTweet-
Great collaboration with @MichaelDJain and @lisa_masucci - our opinion peace in Molecular Therapy re: the high cost of cellular therapies. https://t.co/EmoNt7fb9p
-
-
Mashup Score: 5Current Clinical Applications of In Vivo Gene Therapy with AAVs - 1 year(s) ago
Researchers have been trying to develop therapies for hereditary diseases for more than 30 years. Several problems have been successfully resolved and thus Tremblay and colleagues are describing the recent progress of clinical applications of gene therapy. There are now several in vivo treatments under trials, and some approved for commercialization.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
Most-read Molecular Therapy paper: Current Clinical Applications of in vivo Gene Therapy with AAVs @ASGCTherapy @MolTherapy @CIHR_IRSC https://t.co/DbWgPX1z8W
-
-
Mashup Score: 3A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19 - 1 year(s) ago
Described here is the first reported therapeutic based on lipid-nanoparticle delivery of small interfering RNAs targeted to inhibit the genome of SARS-COV-2 as a treatment for COVID-19.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
Most-read paper from Molecular Therapy: A #SARS-CoV-2 targeted siRNA-nanoparticle therapy for #COVID-19 @ASGCTherapy @MolTherapy @MenziesHealth https://t.co/shyH4qKmmF
-
-
Mashup Score: 0Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit - 2 year(s) ago
Neil Bhowmick and colleagues found that targeting CD105 with carotuximab, inhibiting bone morphogenic protein signaling, affected a recognized hormone therapy resistance. Combining carotuximab with hormone therapy limited tumor progression in mouse models as well as supporting progression-free survival of patients determined to be resistant to hormone therapy alone.
Source: Molecular TherapyCategories: Hem/Oncs, Latest HeadlinesTweet-
Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit: Molecular Therapy https://t.co/GWj1cJtKt4
-
Newly developed mRNA vaccines against #Zika and #HIV-1 produce strong antibody responses that transfer from pregnant rabbits to their offspring. @KhandharAmit Read more in @MolTherapy https://t.co/g70eTGblVI